- Home
- SLXN vs ALZN Comparison
SLXN vs ALZN Comparison
Compare SLXN & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- ALZN
- Stock Information
- Founded
- SLXN 2008
- ALZN 2016
- Country
- SLXN Israel
- ALZN United States
- Employees
- SLXN N/A
- ALZN N/A
- Industry
- SLXN
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- SLXN
- ALZN Health Care
- Exchange
- SLXN NYSE
- ALZN Nasdaq
- Market Cap
- SLXN 5.2M
- ALZN 6.1M
- IPO Year
- SLXN N/A
- ALZN 2021
- Fundamental
- Price
- SLXN $0.69
- ALZN $1.17
- Analyst Decision
- SLXN Strong Buy
- ALZN Strong Buy
- Analyst Count
- SLXN 1
- ALZN 1
- Target Price
- SLXN $9.00
- ALZN $32.00
- AVG Volume (30 Days)
- SLXN 1.4M
- ALZN 145.7K
- Earning Date
- SLXN 02-21-2025
- ALZN 12-12-2024
- Dividend Yield
- SLXN N/A
- ALZN N/A
- EPS Growth
- SLXN N/A
- ALZN N/A
- EPS
- SLXN N/A
- ALZN N/A
- Revenue
- SLXN N/A
- ALZN N/A
- Revenue This Year
- SLXN N/A
- ALZN N/A
- Revenue Next Year
- SLXN N/A
- ALZN N/A
- P/E Ratio
- SLXN N/A
- ALZN N/A
- Revenue Growth
- SLXN N/A
- ALZN N/A
- 52 Week Low
- SLXN $0.21
- ALZN $1.06
- 52 Week High
- SLXN $13.56
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- ALZN 45.87
- Support Level
- SLXN N/A
- ALZN $1.13
- Resistance Level
- SLXN N/A
- ALZN $1.23
- Average True Range (ATR)
- SLXN 0.00
- ALZN 0.06
- MACD
- SLXN 0.00
- ALZN 0.01
- Stochastic Oscillator
- SLXN 0.00
- ALZN 37.20
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.